Bristol Myers Squibb Press Releases https://bristolmyers2016ir.q4web.com/generated by Q4Thu, 10 Sep 2026 16:37:59 -0400Copyright Q4 Inc. All rights reserved.Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...0b9405b1-4467-4d9e-8128-89adcb4a6c28https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Registrational-Phase-2-QUINTESSENTIAL-Trial-of-the-Potential-First-in-Class-GPRC5D-Directed-CAR-T-Cell-Therapy-Arlocabtagene-Autoleucel----/default.aspxTue, 08 Sep 2026 06:59:00 -0400Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 20261cf9ed87-118d-4f0e-9a71-2e9687bbe2b3https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Presents-Data-Up-to-Five-Years-Reinforcing-the-Long-Term-Efficacy-and-Safety-of-Camzyos-mavacamten-in-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM-at-the-European-Society-of-Cardiology-ESC-Congress-2026/default.aspxSat, 29 Aug 2026 11:00:00 -0400U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapsec3e998b3-55a1-480a-a27a-5e80bf9956e8https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/U-S--FDA-Grants-Accelerated-Approval-to-Bristol-Myers-Squibbs-First-CELMoD-Therapy-ZENBEXUS-in-Combination-with-Daratumumab-and-Hyaluronidase-fihj-and-Dexamethasone-ZDd-for-Patients-with-Multiple-Myeloma-as-Early-as-First-Relapse/default.aspxThu, 13 Aug 2026 17:12:00 -0400Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas23d92323-1cbe-4f9b-b073-6f6912904dabhttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Advances-U-S--Manufacturing-Investment-with-New-2-3-Billion-Campus-in-Houston-Texas/default.aspxMon, 10 Aug 2026 09:01:00 -0400Bristol Myers Squibb Reports Second Quarter Financial Results for 202605e849c5-7a6e-4c8c-abd6-2ee239f32c3chttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2026/default.aspxThu, 30 Jul 2026 06:59:00 -0400Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA8c9397b5-f92e-45f1-8ee7-578b6f4a00c0https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-to-Build-the-Most-Powerful-AI-Factory-in-Life-Sciences-with-NVIDIA/default.aspxMon, 20 Jul 2026 06:59:00 -0400U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma5940acab-e238-4eab-8cb8-5bbaa1be65abhttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/U-S--Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Mezigdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxMon, 13 Jul 2026 06:59:00 -0400Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026fdf1bdda-8191-4192-b48e-07e4cc8b5659https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-to-Report-Results-for-Second-Quarter-2026-on-July-30-2026/default.aspxThu, 18 Jun 2026 06:59:00 -0400Bristol Myers Squibb Announces Dividend8fed0070-b0f9-43e0-9881-4f56f0d1885ehttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Announces-Dividend-d189f3983/default.aspxWed, 17 Jun 2026 16:16:00 -0400Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease2c9c508b-5d33-4e0c-a153-a9752a534267https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Mariska-Hargitay-Partners-with-Bristol-Myers-Squibb-for-Investigating-Myeloma-Awareness-Campaign-to-Honor-Her-Father-20-Years-After-Losing-Him-to-the-Disease/default.aspxMon, 08 Jun 2026 06:59:00 -0400